A systematic review of the impact of botulinum-A toxin as a therapeutic regimen for the management of adult migraine disorders is shown to that Botulinum-A toxin provides a more significant reduction in the number of headache episodes per month relative to placebo (MD: -0.61, 95% CI: -1.02 to -0.19). In subgroup analysis, botulinum-A toxin significantly reduced headache episodes per month relative to placebo for chronic migraine (MD: -1.68, 95% CI: -3.31 to -0.06), migraine (MD: -2.43, 95% CI: -4.08 to -0.77), and follow-up time in 16 weeks (MD: -2.19, 95% CI: -3.84 to -0.53). Statistical differences were not found in subgroup analyses of data relating to chronic migraine, episodic migraine, and other treatment course durations. An analysis of chronic and episodic migraine, botulinum-A toxin did not significantly differ from placebo in the proportion of patients achieving a fifty percent reduction in the number of headaches per month. In terms of patients’ subjective reporting of headaches, botulinum toxin A conferred significant improvements when assessment questionnaires of migraine disability and migraine impact were analyzed. However, differences were not substantial with data from the 6-item headache impact test. This meta-analysis demonstrated that botulinum-A toxin as a therapeutic regimen improved the impact of chronic migraines after 16 weeks of therapy, although this was not the case for episodic migraine.
Cite this article
Impact of the botulinum-A toxin on prevention of adult migraine disorders
1 Jiangsu Vocational College of Medicine, Yancheng, 224005, P. R. China
2 Hubei University of Chinese Medicine, Wuhan, 430065, P. R. China
3 Institute of Chinese Medicine Nephrology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan, 430061, P. R. China
*Correspondence: email@example.com (Lan Wang)
J. Integr. Neurosci. 2020, 19(1), 201–208; https://doi.org/10.31083/j.jin.2020.01.1240
Submitted: 19 November 2019 | Accepted: 24 February 2020 | Published: 30 March 2020
Copyright: © 2020 Shen and Wang. Published by IMR press.
This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0/).
treatment-related adverse events